BRPI0410936A - pró-fármaco inibidor da beta-lactamase - Google Patents

pró-fármaco inibidor da beta-lactamase

Info

Publication number
BRPI0410936A
BRPI0410936A BRPI0410936-8A BRPI0410936A BRPI0410936A BR PI0410936 A BRPI0410936 A BR PI0410936A BR PI0410936 A BRPI0410936 A BR PI0410936A BR PI0410936 A BRPI0410936 A BR PI0410936A
Authority
BR
Brazil
Prior art keywords
beta
mammal
present
lactam antibiotic
prodrug
Prior art date
Application number
BRPI0410936-8A
Other languages
English (en)
Inventor
Anthony Marfat
Dale Gordon Mcleod
John Paul O'donnell
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0410936A publication Critical patent/BRPI0410936A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/86—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with only atoms other than nitrogen atoms directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D499/861—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with only atoms other than nitrogen atoms directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with a hydrocarbon radical or a substituted hydrocarbon radical, directly attached in position 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/12—1,4-Dioxanes; Hydrogenated 1,4-dioxanes not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"PRó-FáRMACO INIBIDOR DA BETA-LACTAMASE". São descritos pró-fármacos de sulfona do ácido 6-beta-hidro-ximetilpenicilânico com a estrutura em que R é H ou metila, cada X é metileno e Y é O, ou em que R é H, cada X é O e Y é metileno, e seus solvatos. São também descritas formulações farmacêuticas compreendendo um pró-fármaco da presente invenção, ou um seu solvato, um antibiótico de beta-lactama opcional e, pelo menos, um veículo farmaceuticamente aceitável. é ainda descrito um método para aumentar a eficácia terapêutica de um antibiótico de beta-lactama num mamífero através da administração de uma quantidade eficaz de um antibiótico de beta-lactama e uma quantidade para aumento da eficácia de um pró-fármaco da presente invenção, ou um seu solvato. é por outro lado descrito um método para tratar uma infecção bacteriana num mamífero através da administração de uma quantidade terapeuticamente eficaz de uma formulação farmacêutica da presente invenção a um mamífero necessitado daquela.
BRPI0410936-8A 2003-06-05 2004-05-24 pró-fármaco inibidor da beta-lactamase BRPI0410936A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47645603P 2003-06-05 2003-06-05
US49842203P 2003-08-27 2003-08-27
PCT/IB2004/001824 WO2004108733A1 (en) 2003-06-05 2004-05-24 Beta-lactamase inhibitor prodrug

Publications (1)

Publication Number Publication Date
BRPI0410936A true BRPI0410936A (pt) 2006-06-27

Family

ID=33514083

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410936-8A BRPI0410936A (pt) 2003-06-05 2004-05-24 pró-fármaco inibidor da beta-lactamase

Country Status (14)

Country Link
US (1) US20050004093A1 (pt)
EP (1) EP1636240A1 (pt)
JP (1) JP2006526612A (pt)
AR (1) AR044482A1 (pt)
BR (1) BRPI0410936A (pt)
CA (1) CA2528065A1 (pt)
CL (1) CL2004001343A1 (pt)
MX (1) MXPA05012895A (pt)
NL (1) NL1026340C2 (pt)
PA (1) PA8604001A1 (pt)
PE (1) PE20050629A1 (pt)
TW (1) TW200504010A (pt)
UY (1) UY28340A1 (pt)
WO (1) WO2004108733A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8579701A1 (es) * 2002-08-23 2005-05-24 Pfizer Prod Inc Profarmaco inhibidor de beta-lactamasa
EP2279796B1 (de) 2002-10-14 2020-12-30 H. Börger & Co. GmbH Verfarhen und vorrichtung zum fördern von pulverförmigem material
US9737505B2 (en) 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
GB201407506D0 (en) 2014-04-29 2014-06-11 Glaxosmithkline Ip Dev Ltd Novel compound

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE34011B1 (en) * 1969-03-13 1975-01-08 Leo Pharm Prod Ltd New penicillin esters
IE34019B1 (en) * 1969-03-18 1975-01-08 Leo Pharm Prod Ltd New semi-synthetic penicillin esters
US3957764A (en) * 1969-11-11 1976-05-18 Lovens Kemiske Fabrik Produktionsaktieselskab 6-aminopenicillanic acid derivatives
US3862181A (en) * 1970-10-28 1975-01-21 Squibb & Sons Inc Process for preparing cephalosporins
US4397783A (en) * 1979-03-05 1983-08-09 Pfizer Inc. Process for converting 6,6-disubstituted penicillanic acid derivatives to the 6-β-congeners
US4287181A (en) * 1979-10-22 1981-09-01 Pfizer Inc. Derivatives of 6β-hydroxyalkylpenicillanic acids as β-lactamase inhibitors
US4432970A (en) * 1979-11-23 1984-02-21 Pfizer Inc. 6-beta-Halopenicillanic acid 1,1-dioxides as beta-lactamase inhibitors
GB2076812A (en) * 1980-05-22 1981-12-09 Ciba Geigy Ag Penam-dioxide compounds, processes for their manufacture, and their use
AU559689B2 (en) * 1981-09-22 1987-03-19 Kureha Kagaku Kogyo K.K. Penicillin derivative
US4406887A (en) * 1981-10-13 1983-09-27 Bristol-Myers Company Method for treating resistant bacteria including anaerobes
US4377590A (en) * 1982-05-10 1983-03-22 Pfizer Inc. Derivatives of ampicillin and amoxicillin with beta-lactamase inhibitors
US4428935A (en) * 1982-05-24 1984-01-31 Pfizer Inc. Penicillanic acid dioxide prodrug
US4826833A (en) * 1984-01-30 1989-05-02 Pfizer Inc. 6-(Substituted)methylene-penicillanic and 6-(substituted)hydroxymethylpenicillanic acids and derivatives thereof
US4521533A (en) * 1984-07-12 1985-06-04 Pfizer Inc. Salts of 6-alpha-(aminomethyl)penicillanic acid 1,1-dioxide esters and beta-lactam antibiotics
US4762921A (en) * 1985-04-18 1988-08-09 Pfizer Inc. 6-(1-acyl-1-hydroxymethyl)penicillanic acid derivatives
US5200403A (en) * 1987-07-10 1993-04-06 Farmitalia Carlo Erba S.R.L. Inhibition of βlactamase with 6 β-(substituted methyl)-penicillanic acid derivatives
JPH03206038A (ja) * 1990-01-08 1991-09-09 Yoshitomi Pharmaceut Ind Ltd 抗菌剤
GB9001405D0 (en) * 1990-01-22 1990-03-21 Leo Pharm Prod Ltd New intermediates,their production and use
ATE186537T1 (de) * 1990-08-20 1999-11-15 Suntory Ltd Antibakterielle penem-ester derivate
GB9208492D0 (en) * 1992-04-16 1992-06-03 Glaxo Spa Heterocyclic compounds
ATE219085T1 (de) * 1997-12-29 2002-06-15 Res Corp Technologies Inc 2-beta-substituierte-6-alkylidenpenizillansäure derivate als beta-laktamase inhibitoren
ATE288438T1 (de) * 1999-03-03 2005-02-15 Astur Pharma Sa Verfahren zur herstellung von dioxopenicillansäurederivaten
PA8579701A1 (es) * 2002-08-23 2005-05-24 Pfizer Prod Inc Profarmaco inhibidor de beta-lactamasa

Also Published As

Publication number Publication date
AR044482A1 (es) 2005-09-14
EP1636240A1 (en) 2006-03-22
CL2004001343A1 (es) 2005-04-22
NL1026340C2 (nl) 2005-09-14
NL1026340A1 (nl) 2004-12-07
MXPA05012895A (es) 2006-02-22
PA8604001A1 (es) 2004-12-16
WO2004108733A1 (en) 2004-12-16
CA2528065A1 (en) 2004-12-16
JP2006526612A (ja) 2006-11-24
UY28340A1 (es) 2005-01-31
TW200504010A (en) 2005-02-01
PE20050629A1 (es) 2005-08-25
US20050004093A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
BR0015051A (pt) Compostos inibidores tricìclicos de poli(adp-ribose) polimerase, seu sal farmaceuticamente aceitável, pró-droga, metabólito ativo, ou solvato, composição farmacêutica, método de inibição da atividade de parp de uma enzima e método de inibição da atividade de enzima parp em tecido de mamìfero
LU92323I2 (fr) La combinaison de (a) dextromethorphan ou un de ses sels pharmaceutiquement acceptables, précursers ou dérivés, par ex. hydrobromure de dextromethorphan et en particulier hydrobromure de dextromethorphan monohydrate;et (b) quinidine ou un de ses selspharmacuetiquement acceptables, précurseurs ou dé rivés, par ex. sulfate de quinidine et en particulier sulfate de quinidine dihydrate
BRPI0008614B8 (pt) composto inibidor tricíclico de poli(adp-ribose) polimerase, e composição farmacêuticas contendo tal composto.
PA8486001A1 (es) Composiciones de celecoxib
MX340965B (es) Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular.
GEP20063890B (en) Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
WO2004002999A8 (en) Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
PA8485601A1 (es) Azalidas de 13 miembros y su uso como agentes antibioticos.
ATE340184T1 (de) Makrolidantibiotika
AR050838A1 (es) Formulacion farmaceutica. para el tratamiento de una infeccion optica
PA8489501A1 (es) Antibioticos cetolidos
BR0010938A (pt) Derivados da 13-metil eritromicina
ES2196331T3 (es) Derivados macrociclicos de cadena de 13 elementos de las eritromicinas a y b.
ATE260928T1 (de) Ketolidantibiotika
BR0309757A (pt) 6-alquilideno-penemas bicìclicos como inibidores de beta-lactamases
PT1109560E (pt) Compostos uteis como inidores de aicarft
UY27947A1 (es) Prófarmaco ihnibidor de beta-lactamasa
CA2351829A1 (en) Macrolide antibiotics
MXPA05012895A (es) Profarmaco inhibidor de beta-lactamasa.
BR0212077A (pt) Compostos de aminopirróis como agentes antiinflamatórios
DOP2003000686A (es) Profarmaco inhibidor de beta-lactamasa
BR0000011A (pt) Composições injetáveis de alatrofloxacina pré-mistruadas
DOP2004000918A (es) Profarmaco inhibidor de beta-lactamasa
WO2005004880A8 (en) Vaginal compositions for treating pelvic tissue infections and traumas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.